



- (51) **International Patent Classification:**
C07K 16/42 (2006.01) *A61P 37/08* (2006.01)
- (21) **International Application Number:**
PCT/US2024/037846
- (22) **International Filing Date:**
12 July 2024 (12.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/526,570 13 July 2023 (13.07.2023) US
63/605,695 04 December 2023 (04.12.2023) US
- (71) **Applicants:** **INHIBRX BIOSCIENCES, INC.** [US/US];
11025 N.Torrey Pines Road, Suite 140, La Jolla, California
92037 (US). **PHYLAXIS BIOSCIENCE, LLC** [US/US];
100 Fillmore Street, #500, Denver, Colorado 80206 (US).
- (72) **Inventors:** **BECKLUND, Bryan R.**; c/o Inhibrx Bio-
sciences, Inc., 11025 N.Torrey Pines Road, Suite 140, La
Jolla, California 92037 (US). **JONES, Kyle S.**; c/o Inhibrx
Biosciences, Inc., 11025 N.Torrey Pines Road, Suite 140,
La Jolla, California 92037 (US). **ECKLES, Andrew M.**;
c/o Inhibrx Biosciences, Inc., 11025 N.Torrey Pines Road,

Suite 140, La Jolla, California 92037 (US). **ECKELMAN, Brendan P.**; c/o Inhibrx Biosciences, Inc., 11025 N.Torrey Pines Road, Suite 140, La Jolla, California 92037 (US). **YAO, Tony Dung-Ling**; c/o Phylaxis BioScience, LLC, 100 Fillmore Street, #500, Denver, Colorado 80206 (US).

- (74) **Agent:** **XU, Lily** et al.; Goodwin Procter LLP, 100 Northern
Avenue, IP DOCKETING DEPT./7TH FL, Boston, Mass-
achusetts 02210 (US).

- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

- (54) **Title:** IGE BINDING PROTEINS AND USES THEREOF




FIG. 1G

- (57) **Abstract:** Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

17 April 2025 (17.04.2025)